CVS Health Helps Customers Accelerate Biosimilar Adoption Through Formulary Changes - Supporting Affordable Options for Osteoporosis Care
CVS HealthCVS Health(US:CVS) Prnewswire·2026-02-05 13:00

Core Viewpoint - CVS Health is enhancing access to lower-cost biosimilar medications, specifically osteoporosis treatments, by introducing new options in its formulary, which will be effective from April 1, 2026, providing significant cost savings compared to original brands [1]. Group 1: Introduction of Biosimilars - CVS Caremark will add osteoporosis biosimilars Ospomyv and Stoboclo, along with generic teriparatide options Bonsity and Tymlos, to its major national commercial template formularies [1]. - These biosimilars will replace Prolia and Forteo, offering customers more affordable alternatives with strong clinical and supply confidence [1]. Group 2: Cost Savings and Strategy - The preferred biosimilar approach is over 50% lower in costs per prescription compared to the original brand [1]. - CVS Caremark's biosimilar formulary strategy has already helped customers realize $1.5 billion in gross savings [5]. - The company has successfully transitioned 96% of its client members using Humira to a biosimilar, demonstrating its commitment to driving competition and cost savings [5]. Group 3: Specialty Drug Management - CVS Specialty proactively informs prescribers and patients about formulary changes, ensuring a smooth transition to covered alternatives [6]. - Advanced technology capabilities streamline the prescription process for doctors, allowing for quick approvals and enhancing patient communication [7]. Group 4: Importance of Biosimilars - Biosimilars are crucial for treating complex chronic conditions and are often injectable medications that require careful handling [8]. - The introduction of Ospomyv and Stoboclo is significant for treating osteoporosis, which is vital for preventing fractures and maintaining independence in older adults [9][10]. Group 5: Company Overview - CVS Health operates approximately 9,000 retail pharmacy locations and serves around 87 million plan members through its pharmacy benefits manager [11]. - The company aims to connect consumers to better health through personalized, technology-driven services, ultimately lowering overall healthcare costs [11].

CVS Health Helps Customers Accelerate Biosimilar Adoption Through Formulary Changes - Supporting Affordable Options for Osteoporosis Care - Reportify